Molecular Signatures of Cutaneous Dupilumab Response

Recruiting now · Phase 4

Conditions studied: Atopic Dermatitis

In brief

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Key facts

Study ID

NCT05858619

Run by

University of California, San Francisco

People needed

15

Starts

2023-02-01

Expected to finish

2028-02-01

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7

You may not qualify if…

• Known pregnancy
• Known immunodeficiencies
• Known parasitic infection -

Where it is running

• University of California, San Francisco — San Francisco, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.